Mouhanad Al-Fakih, MD
Internal Medicine · Connellsville, PANPI 1013914605
Payments from drug & device makers
Across 687 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Novo Nordisk$1K
- Lilly USA, LLC$946
- Bayer$671
- Pfizer$639
- plus $6K from 39 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$1001%
- Food & beverage$11,81396%
- Education$3343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,247 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $249,694 |
| XareltoRivaroxaban | 386 | $161,382 |
| OzempicSemaglutide | 139 | $138,894 |
| JardianceEmpagliflozin | 121 | $106,675 |
| IngrezzaValbenazine Tosylate | 25 | $103,063 |
| TrulicityDulaglutide | 124 | $101,867 |
| FarxigaDapagliflozin Propanediol | 221 | $101,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $74,922 |
| GlatopaGlatiramer Acetate | 50 | $60,052 |
| MounjaroTirzepatide | 68 | $56,208 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $53,962 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $46,814 |
| JanuviaSitagliptin Phosphate | 70 | $46,385 |
| RybelsusSemaglutide | 35 | $45,209 |
| TradjentaLinagliptin | 104 | $44,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $639 | $260,071460 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,085 | $199,526211 claims |
| Johnson & JohnsonXarelto, Procrit | $610 | $179,410410 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $499 | $173,211248 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $946 | $158,075192 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,176 | $148,957264 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $1,467 | $146,948320 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $38 | $103,06325 claims |
| MerckJanuvia, Janumet | $115 | $58,56486 claims |
| AbbVieLinzess, Creon | $364 | $54,206102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $417 | $33,25919 claims |
| NovartisEntresto | $240 | $20,91062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Connellsville
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.